hypomagnesemia. Disorders of magnesium metabolism
Conditions
Interventions
Intervention 1: Intervention group: Correction of the patient s hypomagnesemia by administering continuous infusion of magnesium sulfate (7.5 gram magnesium sulfate manufactured by Daro Pakhsh industr
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Hypomagnesemia patients hospitalized in the intensive care unit Less than 96 hours have passed since ICU admission. written consent to enter the study
Exclusion criteria
Exclusion criteria: Magnesium serum concentration higher than 4 mg/dl Stage IV, V CKD based on the Cockcroft-Gault formula heart rate less than 50 times per minute, 2nd and 3rd degree heart block receiving a high dose of furosemide (more than 3 mg/hr) The need to receive magnesium outside the protocol History of muscle weakness disease (MS, Guillain-Barre, botulism, myasthenia gravis) Refractory shock (EP ? NEP > ?? mcg/min ) survival less than 48 hours Patients with AKI massive blood transfusion unable to take a urine sample for any reason?
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of patients who have more than 50% magnesium retention at the end of the study. Timepoint: Urine collection 24 hours after magnesium administration. Method of measurement: 24-hour urine collection and examination of magnesium excreted in 24-hour urine. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the percentage of urinary magnesium excreted compared to the baseline condition. Timepoint: Measurement of urine magnesium before starting treatment and after finishing treatment. Method of measurement: Measurement of urine magnesium after 24hour. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarhad Najmeddin
Tehran University of Medical Sciences
Outcome results
None listed